CD30 as a Therapeutic Target for Lymphoma


Hodgkin’s lymphoma (HL) and ALK+ anaplastic large-cell lymphoma (ALCL) have become highly curable due to the success of modern regimens of chemotherapy and radiotherapy. However, up to one-third of the patients experience relapse or do not respond to first-line therapy, and half of them relapse again after secondary therapy with limited options for further… (More)
DOI: 10.1007/s40259-013-0068-8


4 Figures and Tables

Slides referencing similar topics